Buserelin

Rex N. Brogden, R N Brogden, Micaela M.-T. Buckley, M M Buckley, Alan Ward, A Ward
Drugs · 1990 · vol. 39(3) , pp. 399–437 · doi:10.2165/00003495-199039030-00007 · PMID:2109679 · W2058477275
review OA: closed CC0 ⤵ 6 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-09 ⓘ

Buserelin, a GnRH agonist, treats hormone-dependent conditions by reversibly desensitizing pituitary gonadotrophins, offering benefits in oncology, gynecology, and infertility with a favorable side effect profile.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

This paper reviews buserelin, a GnRH agonist, focusing on its pharmacodynamics, pharmacokinetics, and therapeutic use across gynecologic, andrologic, pediatric, and oncologic conditions. It describes how single doses stimulate pituitary gonadotropin release but repeated dosing causes reversible pituitary desensitization with suppression of sex-steroid production and inhibition of ovulation; it also notes limitations such as uncertainty about long-term hypoestrogenic effects on bone mineral content and that endometrial proliferation findings vary between studies at lower doses. Regarding endometriosis, the paper reports noncomparative trials using intranasal buserelin (often 300 μg three times daily for about 6 months) in which dysmenorrhea and pelvic pain improve and repeat laparoscopy shows a 70–80% reduction in active implant scores, with symptoms recurring in some patients after cessation and with higher recurrence in initially severe disease. This paper is centrally about endometriosis—specifically summarizing buserelin’s mechanism, tolerability, trial outcomes on symptom and implant score reduction, and the pattern of transient remission with recurrence after stopping treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Buserelin Animals Buserelin Buserelin Buserelin Buserelin Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (6)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
unpaywall
last seen: 2026-06-05T02:00:03.366016+00:00
License: CC0 · commercial use OK